Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Assets (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Assets for 16 consecutive years, with $102.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 58.01% to $102.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $102.4 million through Dec 2025, up 58.01% year-over-year, with the annual reading at $102.4 million for FY2025, 58.01% up from the prior year.
  • Current Assets for Q4 2025 was $102.4 million at Gyre Therapeutics, up from $98.6 million in the prior quarter.
  • The five-year high for Current Assets was $116.5 million in Q1 2021, with the low at $5.1 million in Q3 2023.
  • Average Current Assets over 5 years is $60.9 million, with a median of $60.0 million recorded in 2023.
  • The sharpest move saw Current Assets tumbled 90.63% in 2023, then skyrocketed 967.99% in 2024.
  • Over 5 years, Current Assets stood at $51.5 million in 2021, then decreased by 3.54% to $49.7 million in 2022, then grew by 15.24% to $57.2 million in 2023, then grew by 13.22% to $64.8 million in 2024, then skyrocketed by 58.01% to $102.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $102.4 million, $98.6 million, and $91.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.